VR 096 - Janssen Biotech/Vectura

Drug Profile

VR 096 - Janssen Biotech/Vectura

Alternative Names: VR096

Latest Information Update: 06 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Biotech; Vectura
  • Class Anti-inflammatories
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 06 Jan 2015 Vectura and Janssen enter into a global development and license agreement to develop anti-inflammatory therapies for Asthma and Chronic obstructive pulmonary disease
  • 06 Jan 2015 Phase-II clinical trials in Asthma in United Kingdom (Inhalation)
  • 06 Jan 2015 Phase-II clinical trials in Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top